High N-terminal pro-B-type natriuretic peptide: a biomarker of lung cancer?
Fiche publication
Date publication
septembre 2010
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BERNARD Alain
Tous les auteurs :
Aujollet N, Meyer M, Cailliod R, Combier F, Coignet Y, Campard S, Facy O, Bernard A, Girard C
Lien Pubmed
Résumé
BACKGROUND: The level of N-terminal pro-B-type natriuretic peptide (NT-proBNP) is affected by many known factors. Our study aimed to evaluate whether other factors, in particular lung cancer, could be responsible for an increase in NT-proBNP levels in a population with no known risk factors for elevated NT-proBNP. PATIENTS AND METHODS: This study was based on the RIABO (Recueil de l'Ischemie au Bloc Operatoire) database, a single-center registry that prospectively records in elective noncardiac surgery. Patients aged > 75 years and those presenting with 1 or more known risk factors for high NT-proBNP were excluded. Patients were divided into 2 groups according to preoperative NT-proBNP levels: (>/= 125 pg/mL or < 125 pg/mL). RESULTS: Between October 2005 and February 2007, 439 patients were eligible for inclusion. Among 35 patients with lung cancer, 26 (74%) had elevated NT-proBNP (>/= 125 pg/mL), versus 9 (26%) with NT-proBNP < 125 pg/mL (P < .0001). By multivariate analysis, the presence of lung cancer was an independent risk factor for a level of NT-proBNP >/= 125 pg/mL (odds ratio, 7; 95% CI, 2.9-17; P < .0001). We also observed an independent relationship between NT-proBNP >/= 125 pg/mL and age, female sex, smoking status, and C-reactive protein levels. CONCLUSION: In our study, patients with lung cancer were 7 times more likely to have elevated NT-proBNP (>/= 125 pg/mL). The presence of lung cancer should therefore be taken into account when interpreting NT-proBNP levels. Further studies are warranted to explore the diagnostic value of this marker in lung cancer and to identify the cause of the elevation.
Référence
Clin Lung Cancer. 2010 Sep 1;11(5):341-5.